The gene therapy space has been a particularly popular niche for investors for quite a while and investors are increasingly interested in discovering new stocks in that space.
On Thursday, the gene therapy company Genprex Inc (NASDAQ: GNPX) was in focus among investors and ended the day with gains of as big as 20%. While the gains made by the stock were attractive there was no news with regards to Genprex that might have led to this particular rally.
In this regard, it might be a good idea for investors to take a look at a key development from March 30. At the time, the company revealed the preclinical data from its immunogene therapy TUSC2 is going a part of as many as two presentations to be made by the company. The presentations are going to take place at the annual meet hosted by the American Association for Cancer Research. The meet in question is beginning today and will continue up until April 14.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.